scispace - formally typeset
M

Michel Farnier

Researcher at Regeneron

Publications -  105
Citations -  7627

Michel Farnier is an academic researcher from Regeneron. The author has contributed to research in topics: Alirocumab & PCSK9. The author has an hindex of 28, co-authored 105 publications receiving 4785 citations. Previous affiliations of Michel Farnier include Merck & Co. & French Institute of Health and Medical Research.

Papers
More filters
Journal ArticleDOI

Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

Antonio J. Vallejo-Vaz, +723 more
- 07 Sep 2021 - 
TL;DR: The European Atherosclerosis Society Familial Hypercholesterolaemia Studies Collaboration (FHSC) global registry provides a platform for the global surveillance of familial hypercholesterololaemia through harmonisation and pooling of multinational data as discussed by the authors.
Journal ArticleDOI

The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential

Jean-Charles Fruchart, +62 more
TL;DR: In this paper, the authors developed a selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) for the treatment of atherogenic dyslipidemia.
Journal ArticleDOI

PCSK9: From discovery to therapeutic applications.

TL;DR: A dramatic decrease in LDL-C up to 70% can be obtained with the most efficacious doses, and large phase III programmes are ongoing to evaluate the long-term efficacy and safety of these very promising new agents.